It is indeed a great achievement for everyone in the TB world to have worked on the front lines and behind the scenes to help facilitate getting the G20 leaders on board to make the historic commitment to combat TB and AMR with necessary investments and programs. I hope this will translate into due investment in training and capacity building in pharmacovigilance of the staff of National TB programs and pharmacovigilance centers.
Syed Rizwanuddin Ahmad, MD, MPH, FISPE, FCP
Pharmacovigilance & Regulatory System Strengthening Consultant
Ex-Consultant/Safety Reviewer, U.S. FDA (1998-2013)
Associate Professor (adjunct), Rutgers School of Public Health, NJ, USA
Assistant Professor (adjunct), Georgetown University School of Medicine,
Washington, DC, USA